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Abstract Peutz–Jeghers syndrome (PJS) is caused by
germline mutations in the LKB1 gene, which encodes a
serine-threonine kinase that regulates cell proliferation
and polarity. This autosomal dominant disorder is
characterized by mucocutaneous melanin pigmentation,
multiple gastrointestinal hamartomatous polyposis and
an increased risk of developing various neoplasms. To
understand the molecular pathogenesis of PJS pheno-
types, we used microarrays to analyze gene expression
proﬁles in proliferating HeLa cells transduced with len-
tiviral vectors expressing wild type or mutant LKB1
proteins. We show that gene expression is diﬀerentially
aﬀected by mutations that impair the kinase activity
(K78I) or alter the cellular localization of the LKB1
protein. However, both mutations abrogate the ability
of LKB1 to up-regulate the transcription of several
genes involved in Wnt signaling, including DKK3,
WNT5B and FZD2. In addition—and in contrast to the
wild type protein—these LKB1 mutants fail to activate
the GSK-3b kinase, which otherwise phosphorylates b-
catenin. The increase in b-catenin phosphorylation that
occurs upon expression of wild-type LKB1 results in
transcriptional inhibition of a canonical Wnt reporter
gene. This suggests that pathogenic LKB1 mutations
that lead to activation of the Wnt/b-catenin pathway
could contribute to the cancer predisposition of PJS
patients.
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Introduction
Peutz–Jeghers syndrome (PJS) is a dominantly inherited
disorder associated with mucocutaneous pigmentation
and gastrointestinal hamartomatous polyposis (OMIM
no. 175200). More than 90% of PJS patients go on to
develop malignancies, about half of which aﬀect the
gastrointestinal tract (Boardman et al. 1998; Giardiello
et al. 2000). The gene responsible for the majority of PJS
cases has been mapped to chromosome 19p13.3 and
found to encode a serine/threonine protein kinase
named LKB1 (alias STK11; Hemminki et al. 1997, 1998;
Jenne et al. 1998). Functional analysis of LKB1 showed
that most mutations observed in PJS patients result in
loss of its kinase activity (Mehenni et al. 1998; Ylikor-
kala et al. 1999; Yoo et al. 2002; Boudeau et al. 2003b).
The LKB1 gene has been conserved during evolution
and is essential for viability. Orthologs have been iden-
tiﬁed in mouse (Smith et al. 1999), Xenopus laevis
(XEEK1; Su et al. 1996), Caenorhabditis elegans (par-4;
Watts et al. 2000), Drosophila melnaogaster (Martin and
St. Johnston 2003) and yeast (Sutherland et al. 2003).
Knockout studies in model organisms demonstrate that
LKB1 plays an essential role in development and
polarity. In C. elegans and Drosophila melanogaster,
LKB1 is required to establish embryonic polarity (Watts
et al. 2000; Martin and St. Johnston 2003) and mice
homozygous for an inactivating LKB1 mutation die at
mid-gestation with multiple developmental defects
including abnormal vasculogenesis (Ylikorkala et al.
2001). In contrast, Lkb1+/ mice are viable and display
no obvious phenotype at birth or in early adult life.
However, such mice later develop gastrointestinal pol-
yps; cells from these polyps express one normal LKB1
allele, suggesting that polyposis arises from haploinsuf-
ﬁciency of LKB1 rather than loss of heterozygosity
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(LOH; Hemminki et al. 1997; Miyoshi et al. 2002).
LKB1 has therefore been deﬁned as a context-dependent
tumor suppressor gene: loss of its function in normal
cells may result in the formation of benign tumors,
whereas its loss in advanced neoplasms could promote
malignant progression (Bardeesy et al. 2002).
In Xenopus LKB1 has recently been shown to func-
tion in the Wnt pathway, regulating GSK-3b activity
during early development (Ossipova et al. 2003). In
mammalian cells, LKB1 triggers phosphorylation of
PAR1A, a kinase that also regulates the Wnt/b-catenin
pathway (Spicer et al. 2003). Activation of this pathway
is crucial for dorso-ventral axis speciﬁcation and is
regulated during embryonic development in lower ver-
tebrates. Constitutive activation of the Wnt pathway is
associated with malignant transformation in adult tis-
sues (Miller 2002; Giles et al. 2003). Lastly LKB1 has
been shown to activate TSC2, a gene that is mutated in
tuberous sclerosis complex, which is an autosomal
dominant syndrome characterized by the development
of benign tumors (Corradetti et al. 2004).
LKB1 is mainly localized in the nucleus, but is also
detected in the cytoplasm and at cell membranes (Smith
et al. 1999; Collins et al. 2000; Sapkota et al. 2001).
Several proteins have been shown to interact with
LKB1, including BRG1 (Marignani et al. 2001), p53
(Karuman et al. 2001), LIP1 (Smith et al. 2001), AGS3
(Blumer et al. 2003) and STRADa (Baas et al. 2003).
Both LIP1 and STRADa anchor LKB1 in the cyto-
plasm. The binding of STRADa to LKB1 also activates
the capacity of the kinase to autophosphorylate, allow-
ing complete polarization of intestinal epithelial cells
(Boudeau et al. 2003a; Baas et al. 2004a). LKB1 has
been shown to form a ternary complex with STRADa
and MO25a, which regulates cell proliferation through
activation of AMP-activated protein kinase (AMPK) by
LKB1-dependent phosphorylation (Hawley et al. 2003;
Hong et al. 2003; Woods et al. 2003). In spite of the
identiﬁcation of these LKB1-interacting proteins (re-
viewed in Boudeau et al. 2003c) carcinogenesis in PJS
remains poorly understood. However, it has recently
been suggested that loss of polarity in epithelial cells
may lead to neoplastic transformation (Baas et al.
2004b).
In this study we investigated whether mutations that
aﬀect the kinase activity or the cellular localization of
LKB1 have similar eﬀects on LKB1 function. To this
end, we compared gene expression proﬁles in HeLa cells
expressing wild type or mutant LKB1. We show here
that the mutations K78I (which eliminates the kinase
activity) and SL26 (associated with nuclear accumula-
tion of LKB1) diﬀerentially aﬀected gene expression
patterns when compared to wild-type LKB1. However,
both mutants failed to induce dephosphorylation of
GSK-3b at residue Ser9, thus maintaining the kinase in
its inactive state. Because b-catenin is a substrate for
GSK-3b and also regulates transcription of Wnt target
genes, we also investigated the phosphorylation state of
b-catenin. We found that the protein was only phos-
phorylated in cells expressing wild-type LKB1. Since
phosphorylated b-catenin is likely to be ubiquitinylated
and then degraded, this allows LKB1 to inhibit the
expression of Wnt-responsive genes in A549 cells. We
showed that this ability is dependent on the kinase
activity of LKB1, since the K78I mutation has no eﬀect
on Wnt signaling. In contrast, expression of the SL26
form of LKB1 further activates expression of a Wnt
reporter gene. Together our results suggest that PJS
mutants may aﬀect the regulation of Wnt/b-catenin
signaling, a pathway which is known to be constitutively
active in many human malignancies.
Materials and methods
Expression vectors and constructs
cDNAs encoding wild-type and mutant LKB1 fused to
the coding sequence for enhanced yellow ﬂuorescent
protein (EYFP) were excised from the pcDNA3 vector
by digestion with NheI (5¢ end) and EcoRI (3¢ end); the
ends were blunted using Klenow enzyme (Roche) and
the fragments were subcloned into pLOX/Ewgfp (Sal-
mon et al. 2000) after digestion of the vector with SalI
and removal of overhangs. The ORFs are inserted
downstream of the EF1alpha promoter and upstream of
the post-transcriptional regulatory element isolated
from woodchuck hepatitis virus (Zuﬀerey et al. 1999).
Cell lines, transfections and lentiviral Infections
HeLa cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen) supplemented with 100 U/
ml penicillin, 100 lg/ml streptomycin, 2 mM L-gluta-
mine, and 10% v/v fetal calf serum (FCS; Invitrogen) in
a 5% CO2 atmosphere at 37C. To produce infectious
viral particles, 293T cells were seeded at a density
106 cells/plate and transfected with three plasmids
expressing (1) the envelope protein of vesicular stoma-
titis virus (pMDG, 10 lg), (2) the packaging system
(pR8.91, 15 lg), and (3) the gene of interest (pLOX/
YFP, pLOX/YFP-LKB-WT, pLOX/YFP-LKB-K78I,
or pLOX/YFP-LKB-SL26; 20 lg). Supernatants from
three plates of transfected 293T cells were pooled, ﬁl-
tered through a Millipore ﬁlter (SLHV 033RS, pore
diameter 0.45 lm), and used to infect one plate of HeLa
cells seeded to a density of 106 cells/plate. Subsequently,
HeLa cultures were expanded for preparation of RNA
for hybridization to Aﬀymetrix microarrays (see below).
FACS analysis
Infected cells were trypsinized and resuspended in
PBS, and YFP ﬂuorescence was directly measured
by FACS. Cell cycle analysis was performed using
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CycleTest Plus (Becton Dickinson) according the
manufacturer’s protocol.
Microarray experiments and quantitative RT-PCR
Total RNA was isolated from cell pellets using an RNA
extraction kit (RNeasy, Qiagen) and treated with DNase
(Qiagen) according to the manufacturer’s protocols.
Infections were performed in triplicate, each providing
one RNA preparation. Two diﬀerent RNA preparations
per sample were then used to generate cRNAs. We
generated a hybridization mixture containing 15 lg
of biotinylated cRNA and hybridized it to human
HG-U133A chips (Aﬀymetrix). Each sample [null (non-
transduced cells), YFP, YFP-LKB-WT, YFP-LKB-
K78I and YFP-LKB-SL26) was analyzed in duplicate,
i.e. for each condition two chips were hybridized and
scanned, and the ﬂuorescence signals were analyzed with
the Aﬀymetrix software MAS 5.0 and DMT 3.0. The
software calculates ‘‘signal’’ values and provides ’detec-
tion’ calls (present, marginal or absent) for each probe
set. Detection calls are determined from statistical
calculations of the diﬀerence in hybridization signals
between perfect match oligonucleotides and their
corresponding control mismatch sequence (probe set).
To identify diﬀerentially expressed transcripts, pairwise
comparison analyses were carried out with Aﬀymetrix
MAS 5.0. Each of the experimental samples was com-
pared with each of the reference samples, resulting in
pairwise comparisons. This approach, which is based on
the Mann-Whitney pairwise comparison test, allows the
ranking of results by concordance, as well as providing
an estimate of the signiﬁcance (P-value) of each identi-
ﬁed change in gene expression (Hubbell et al. 2002; Liu
et al. 2002). Pairwise analyses of the DNA microarray
data obtained with cRNA probes derived from RNA
prepared from non-transduced cells or cells expressing
YFP or wild-type or mutant LKB1 proteins resulted in
four comparison sets. Transcripts were considered to be
diﬀerentially expressed if their levels changed in the
same direction in all four comparisons, if the average
median change was at least twofold, or if the P value
for the median relative change was <0.05. Results are
expressed as the average relative change in the four
comparisons.
Ribonucleic acid preparations from three independent
experiments were used as templates for quantitative RT-
PCR analysis. We carried out quantitative RT-PCRs
according to the manufacturer’s (Applied Biosystems)
protocols using Taqman probes purchased from Euro-
gentec. All primers were designed with Primer Express
Software (Applied Biosystems) and all ampliﬁed frag-
ments corresponded to exon–exon junctions. Samples
were analyzed in triplicate and the raw data consisted of
PCR cycle numbers required to reach a ﬂuorescence
threshold (Ct). Raw Ct values were obtained using SDS
2.0 (Applied Biosystems). Relative expression level of
target genes was normalized according to geNorm
(Vandesompele et al. 2002) using TBP (TATA-binding
protein) and EEF1A1 (eukaryotic translation elongation
factor a-1) as references to determine the normalization
factor. All primer sequences are available on request.
Immunoblot assays
Aliquots (50 lg) of protein extracts were fractionated by
SDS-PAGE on 10–15% polyacrylamide gels. Proteins
were then electrophoretically transferred to nitrocellu-
lose membranes, which were incubated in PBS contain-
ing blocking solution (5% non-fat dry milk and 0.05%
Tween 20) for 1 h at room temperature. We then incu-
bated the membranes either overnight at 4C or for 1.5 h
at room temperature in the blocking solution containing
appropriate antibodies: anti-ﬁbronectin [F 3648 (Sigma),
1:2,000 dilution], anti-IGFBP3 [sc-9028 (Santa Cruz),
1:1000 dilution], anti-HA (Babco, 1:1000 dilution), anti-
b-catenin total [C 2206 (Sigma), 1:8,000 dilution], anti-
phospho-b-catenin T41/S45 [9565 (Cell Signaling),
1:1,000 dilution], anti-phospho-GSK-3b S9 [9336 (Cell
Signaling), 1:1,000 dilution], anti-GSK-3b [G7914 (Sig-
ma), 1:2,000 dilution], anti-actin [MAB1501 (Chem-
icon), 1:2,000] and anti-cyclin D1 [CC12 (Oncogene),
1:100 dilution]. The secondary horseradish peroxidase-
linked antibody to rabbit or mouse IgG was then added
(diluted at 1:8,000 in the blocking solution) and incu-
bated at room temperature for 1 h. We detected
immunoreactivity with a commercially available detec-
tion system (Catalog No. 34075, Pierce), followed by
exposure to Hyperﬁlm ECL (Amersham) for 1–10 min.
Luciferase assays
HeLa or A549 cells were plated in 6-well plates at 50%
conﬂuency and co-transfected with 0.3 lg of pLOX
(pLOX/HA-LKB-WT, pLOX/HA-LKB-K78I, pLOX/
HA-LKB-SL26 or pLOX/HA-LKB-D176N as indi-
cated), 0.7 lg of luciferase reporter vector (ﬁreﬂy,
TOPﬂash or FOPﬂash; a gift from Dr. R. Moon) and
0.2 ug of pRL-TK (Renilla, Promega) using FuGene
Reagent (Roche) according the manufacturer’s protocol.
Fireﬂy and Renilla luciferase activities were determined
24–48 h post transfection using the Dual Luciferase
Reporter Assay System (Promega).
Results
Establishment of viable HeLa cells expressing
LKB1 after lentiviral infection
In order to compare gene expression proﬁles of cells
expressing wild type or mutant LKB1 proteins, we
decided ﬁrst to establish a cell line that does not express
endogenous LKB1 and survives de novo expression of
wild type LKB1. Overexpression of wild-type, but not
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catalytically inactive, LKB1 results in a G1 cell cycle
arrest in tumor cell lines that do not express the
endogenous LKB1 gene (Tiainen et al. 1999; Karuman
et al. 2001; Jimenez et al. 2003). Therefore, we tested the
hypothesis that expression of low levels of LKB1 does
not aﬀect cell growth. For this purpose we used lentiviral
vectors because (1) nearly 100% of infected cells express
the exogenous protein, and (2) the level of protein
expression depends on the promoter used to drive
transcription of the gene of interest and on the number
of integrated proviruses (which is usually between one
and ﬁve copies; Naldini et al. 1996). Hence, we chose to
express wild type (WT) or mutant (K78I and SL26)
LKB1 proteins, driven by the EF1a promoter, from a
lentiviral construct after infection of epithelial HeLa
cells lacking endogenous LKB1 (no LKB1 expression is
detectable at the mRNA or protein level; data not
shown).
These two mutants were chosen for the following
reasons. The LKB1-K78I mutant, unlike the WT pro-
tein, cannot autophosphorylate because of the mutation
of the catalytic residue K78 (Su et al. 1996), and the
K78I substitution is representative of the majority of
loss-of-function LKB1 mutations found in PJS patients
(reviewed in Boudeau et al. 2003c). The LKB1-SL26
mutant was identiﬁed in a PJS patient. It retains its ki-
Fig. 1 FACS analysis showing
viability of HeLa cells
transduced with lentiviral
vectors expressing wild type or
mutant LKB1. Parental HeLa
cells (HeLa) or cells transduced
with lentiviral vectors
expressing YFP, YFP-LKB1-
WT, YFP-LKB1-K78I or YFP-
LKB1-SL26 were analyzed by
FACS 5 days post-infection,
and RNA samples for
microarray analysis were
prepared. a YFP ﬂuorescence
analysis shows that 100% of
cells express the indicated
proteins, and that all fusion
proteins are expressed at similar
levels. b Cell cycle analysis of
the cells described in a were
performed as described in
Materials and methods, and the
percentages of cells in G1, S or
G2/M phases are indicated
187
nase activity but is nevertheless still pathogenic probably
because the mutant protein accumulates in the nucleus
(Nezu et al. 1999). All constructs were tagged with YFP
or the HA (haemagglutinin) epitope, and immunoﬂuo-
rescence experiments were performed to monitor the
cellular localization of the fusion proteins in transduced
cells. As previously described, YFP or HA-tagged
LKB1-K78I displays the same cellular localization as
wild-type LKB1 (i.e. it is found both in the nucleus and
the cytoplasm), whereas LKB1-SL26 accumulates pre-
dominantly in the nucleus (Nezu et al. 1999; Karuman
et al. 2001; data not shown). FACS analysis showed that
all YFP-LKB1 fusion proteins were expressed at similar
levels (Fig. 1a).
No diﬀerence in cell viability was observed when the
cell cycle of HeLa cells expressing WT or mutant LKB1
was analyzed 5 days post-infection, indicating that low
LKB1 expression levels do not aﬀect HeLa cell viability
(Fig. 1b). Five days was the minimum time required for
cells to recover from virus infection and divide suﬃ-
ciently often to provide enough RNA and protein for
further analyses. One major advantage of this expression
system is that, in contrast to previous studies, it does not
induce growth inhibition upon ectopic expression of WT
LKB1; thus transcriptome comparisons between cells
expressing either WT or mutant LKB1 proteins (K78I or
SL26) could be performed. Since the analyses were done
5 days post-infection, the data reﬂect the consequences
of prolonged expression of WT or mutant LKB1 pro-
teins rather than identifying direct targets of LKB1.
Comparative analysis of transcriptomes reveals that
the K78I and SL26 mutations aﬀect LKB1
functions diﬀerentially
In order to investigate how mutations found in PJS
patients might aﬀect LKB1 functions, we compared gene
expression proﬁles between cells expressing wild type or
mutant LKB1 proteins. Microarray analysis was per-
formed using total RNAs from uninfected HeLa cells
and from cells transduced with lentiviral vectors
expressing YFP, YFP-LKB1-WT, YFP-LKB1-K78I or
YFP-LKB1-SL26. cRNAs prepared from all samples
(each analyzed in duplicate) were hybridized to Human
Genome 133A arrays (HG-U133A; Aﬀymetrix) con-
taining 22,500 transcripts. Transcripts were deﬁned as
up-regulated or down-regulated if: (1) variation showed
the same trend in the four comparison sets, (2) the ratio
of the signal intensities was >2 or <0.5 for induced or
repressed genes respectively, or (3) a t test for signiﬁ-
cance yielded a P value of <0.05.
First, we compared uninfected with YFP-transduced
HeLa cells (two arrays each). On the basis of the criteria
listed above, YFP expression has only minor eﬀects on
the transcription proﬁle when compared to uninfected
cells (data not shown). Cells transduced with YFP were
then used as the control for comparison with the cells
transduced with YFP-LKB1-WT. In this analysis we
detected 64 up-regulated and 65 down-regulated tran-
scripts in cells expressing the wild-type LKB1 fusion
compared to YFP alone (see Tables S1 and S2, respec-
tively, in the Electronic Supplementary Material).
Among the up-regulated set were transcripts encoding
PAI1, thrombospondin 1, type IV collagen a1, transgelin
(SM22a) and calponin 3—derived from genes that have
been shown to be transcriptionally activated by the
SMAD4/TGF-b pathway (Dennler et al. 1998; Schwar-
te-Waldhoﬀ et al. 2000). These results indicate that the
cellular system used here is appropriate for functional
analysis of LKB1 since the protein has already been
suggested to play a role in TGF-b signaling (Smith et al.
2001).
We were then interested in identifying genes whose
LKB1-dependent expression is aﬀected by the LKB1
mutations. Further comparisons were therefore per-
formed between cells expressing LKB1-WT and
LKB1-K78I or LKB1-SL26, and diﬀerentially regulated
transcripts are depicted in Fig. 2.
We ﬁrst noted that expression of the two mutants
aﬀected global gene expression diﬀerentially. Indeed
when compared to cells expressing wild type LKB1,
fewer transcripts were misregulated in K78I- (22
transcripts up- and 20 down-regulated; Fig. 2 and
Supplementary Table S3) than in SL26 (90 transcripts
up- and 60 transcripts down-regulated; Fig. 2 and
Supplementary Table S4)-expressing cells. We found
very few transcripts that were speciﬁcally aﬀected by
expression of the K78I variant (two up- and three
down-regulated; shown in yellow in Table S3, and see
Fig. 2a, b). In contrast, upon expression of SL26, 40
up- and 18 down-regulated transcripts were found to
respond speciﬁcally in this mutant (Fig. 2a, b; shown
in yellow in Table S4). Taken together, these results
show that the two mutations are not functionally
equivalent, and suggest that global gene expression is
aﬀected more by a mutation that alters the cellular
Fig. 2 Microarray analysis. Transcripts are grouped as up- (a) or
down (b)-regulated in cells expressing wild type LKB1 and the
numbers of these that are misregulated by a given LKB1 mutation
are indicated. Only transcripts whose levels changed by more than
twofold (ratios >2 or <0.5) are considered, and the following
comparisons were done: K78I versus WT, SL26 versus WT and
WT versus YFP. Each number represents a speciﬁc Net Aﬀyx ID
and is associated with a P<0.05. Numbers in brackets indicate the
total number of transcripts with up- or down-regulated expression
in the comparisons listed above
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localization of LKB1 than one that reduces its kinase
function. Finally, the SL26 mutant exhibits novel
functions, since it induces a speciﬁc cellular response
(transcripts marked in yellow in Supplementary Table
S4).
A common subset of transcripts responds
to both mutant forms of LKB1
The transcriptome comparisons described in the previ-
ous section between HeLa cells expressing normal and
mutant LKB1 revealed that a subset of LKB1-depen-
dent genes is aﬀected by both the K78I and SL26
mutations. For instance, 43 (26+13+1) transcripts that
are up-regulated by LKB1-WT (Fig. 2a) and 44
(33+8+3) transcripts that are down-regulated were
aﬀected by K78I or SL26 mutations (Fig. 2b). A de-
tailed analysis identiﬁed eight transcripts that are
down-regulated by LKB1-WT but not by either of the
LKB1 mutants (Fig. 2a and Table 1; transcripts high-
lighted in blue in Supplementary Tables S3 and S4).
Similarly, LKB1-dependent up-regulation of 13 tran-
scripts is aﬀected by K78I and SL26 mutations (Fig. 2b
and Table 1; transcripts highlighted in blue in Tables S3
and S4). These results suggest that, although the SL26
mutant retains its kinase activity in vitro, it also fails
to regulate some genes that do not respond to the
kinase-dead K78I mutant.
Among these commonly regulated transcripts we
identiﬁed several components of the Wnt signaling
pathway. Wnt proteins are secreted molecules that
transduce signals by binding to two distinct families of
cell surface receptors, namely the Frizzled (Fzd) family
Table 1 Genes diﬀerentially regulated in HeLa cells expressing wild-type versus mutant LKB1 kinase
Net aﬀyx ID Accession no. Gene Relative changea
WT vs. YFP K78I vs. WT SL26 vs. WT
Genes up-regulated by LKB1-WT and down-regulated by LKB1 mutants
203570_at NM_005576 Lysyl oxidase-like 1 (LOXL1) 16.5 0.27 0.1
202628_s_at NM_000602.1 Plasminogen activator inhibitor type 1 (PA1) 8.1 0.2 0.1
204298_s_at NM_002317.1 Lysyl oxidase (LOX) 6.7 0.3 0.2
221029_s_at NM_030775.1 WNT5B 6.5 0.4 0.3
211719_x_at BC005858.1 Unknown (protein for MGC:3255)
215446_s_at L16895 Lysyl oxidase (LOX) gene, exon 7 5.6 0.4 0.2
212143_s_at NM_000598.1 Insulin-like growth factor binding
protein 3 (IGFBP3)
5.3 0.2 0.16
210495_x_at AF130095.1 Fibronectin 1 4.76 0.42 0.19
216442_x_at AK026737.1 Fibronectin 1 4.59 0.43 0.21
214247_s_at AU148057 Dickkopf 3 (DKK3) 4 0.5 0.4
213909_at AU147799 Homo sapiens cDNA FLJ12280
ﬁs, clone MAMMA1001744
4 0.3 0.3
201578_at NM_005397.1 Podocalyxin-like (PODXL) 3.36 0.49 0.35
201952_at L38608.1 Activated leucocyte cell adhesion molecule 3.2 0.5 0.3
Potentially interesting
205547_s_at NM_003186.2 Transgelin (TAGLN) 20.7 0.3 0.1
210220_at NM_001466 Frizzled homolog 2 (FZD2) 3 0.52 0.4
Genes down-regulated by LKB1-WT and up-regulated by LKB1 mutants
204920_s_at W80357 Carbamoyl-phosphate synthetase 1,
mitochondrial (CPS1)
0.05 5.2 21
201926_s_at NM_000574.1 Decay accelerating factor
for complement (CD55)
0.1 4.5 8.1
211919_s_at AF348491.1 Chemokine receptor CXCR4 0.12 3.8 5.9
202946_s_at NM_014962.1 Homo sapiens KIAA0952 protein 0.19 2.98 6.61
217388_s_at D55639.1 Kynureninase (L-kynurenine hydrolase) 0.28 2.73 3.36
209869_at NM_000681.1 Alpha-2A adrenergic receptor mRNA 0.30 2.88 3.8
202388_at NM_002923.1 Regulator of G-protein signaling 2,
24 kD (RGS2)
0.3 2.2 3
202887_s_at NM_019058.1 Hypothetical protein (FLJ20500) 0.36 2.59 3.03
Potentially interesting
202890_at NM_003980 Microtubule-associated protein 7 (MAP7) 0.04 11.3 28
204748_at NM_000963 COX-2 0.15 3.8 2.12
205935_at NM_001451.1 Forkhead box F1 (FOXF1) 0.4 1.9b 2.4
204198_s_at NM_004350.1 Runt-related transcription
factor 3 (RUNX3)
0.4 1.6b 2.2
aExpression levels of transcripts found up- or down–regulated
upon YFP-LKB1-WT were compared with those found in YFP-
LKB1-K78I and YFP-LKB1-SL26 mutant expressing cells. Tran-
scripts whose expression levels are aﬀected by both mutations are
listed. Only transcripts with expression (signal intensity) ratios of
>2 or <0.5 for induced or repressed transcripts, respectively, and
a P value of <0.05 are considered. Relative changes shown in bold
are associated with P values of >0.05
bChanges of less than twofold
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and the LDL-receptor-related-protein (LRP) family. In
contrast, members of the Dickkopf (Dkk) protein
family inhibit Wnt signal transduction. In particular,
we found that transcription of WNT5B and DKK3
(Dickkopf-3) is induced—6.5-fold and fourfold,
respectively—upon stable expression of YFP-LKB1-
WT (Table 1), and these diﬀerences were conﬁrmed by
qRT-PCR (Fig. 3a). The Frizzled-2 gene (FZD2) was
tested by qRT-PCR because it was found to be up-
regulated in LKB1-WT-expressing cells and down-
regulated in cells that express K78I or SL26 (albeit
with a P>0.05 for the K78I vs. WT comparison);
qRT-PCR conﬁrmed the microarray data. Similarly,
COX2, which has been identiﬁed as a target of Wnt
(Araki et al. 2003) is up-regulated twofold to fourfold
in mutant-expressing cells (Table 1). qRT-PCR also
conﬁrmed the microarray data for COX2 (Fig. 3a). As
DKK3 expression is induced and COX2 expression is
repressed in YFP-LKB1-WT but not in mutant-
expressing cells, these results suggest that wild-type
LKB1 inhibits the Wnt signal transduction pathway
and that this function is compromised by mutations in
LKB1.
GSK-3b activation is impaired by the K78I
and SL26 mutations in LKB1
Canonical Wnt signaling is initiated by the formation of
a Wnt-Fzd-LRP complex, resulting in nuclear accumu-
lation of b-catenin and subsequent activation of target
genes. The secreted protein Dickkopf 1 (Dkk1) speciﬁ-
cally inhibits complex formation by binding to the LRP,
thus inhibiting Wnt signaling by preventing accumula-
tion of b-catenin in the nucleus (Baﬁco et al. 2001).
Unphosphorylated b-catenin accumulates in the nucleus
and activates transcription of Wnt target genes con-
taining DNA binding sites for the TCF/LEF family of
transcription factors (TCF-LEF dependent), whereas
phosphorylated b-catenin is degraded by the proteasome
(Miller 2002). Based on the sequence homology between,
and the functional equivalence of, Dkk1 and Dkk3
in vitro (Caricasole et al. 2003), we further tested
the hypothesis that up-regulation of DKK3 in LKB1-
Fig. 3 Expression of WT but not mutant LKB1 proteins in HeLa
cells dys-regulates transcription of several genes involved in the
Wnt signaling and induces b-catenin phosphorylation by activation
of GSK-3b a qRT-PCR was performed on RNA extracts from
parental HeLa cells and from cells expressing WT or mutant (K78I
and SL26) LKB1 proteins. Data are means (± SD) from three
independent experiments analyzed in triplicate. Data are normal-
ized with reference to the housekeeping genes mentioned in
Materials and methods. Data obtained with RNA from HeLa
cells served as reference and the relative changes correspond to the
following ratios: LKB1-WT/HeLa, LKB1-K78I/HeLa, LKB1-
SL26/HeLa. Genes for components of the Wnt signaling pathway
(DKK3, FZD2 and WNT5B) and the Wnt target gene COX2 were
assayed. b, c Lysates of parental HeLa cells (-) or cells tranduced
with HA-LKB1-WT, HA-LKB1-K78I or HA-LKB1-SL26 were
prepared 5 days post-infection and fractionated by SDS-PAGE,
and selected endogenous proteins were detected by immunoblotting
with the following antibodies: anti-b-catenin and T41/S45
phospho-speciﬁc anti-b-catenin antibodies (b), or anti-GSK-3b,
S9 phospho-speciﬁc anti-GSK-3b and anti-HA antibodies (c). Anti-
actin antibodies were used to check that equal amounts of total
proteins (50 lg) had been loaded
b
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WT-expressing cells could inhibit canonical Wnt signal
transduction by inducing phosphorylation of b-catenin.
We used phospho-speciﬁc antibodies to analyze by
Western blotting the phosphorylation state of residues
T41 and S45 of b-catenin in protein extracts from cells
transduced with the empty YFP vector, or the LKB1-
WT, K78I or SL26 construct. We found that b-catenin is
phosphorylated only in LKB1-WT-expressing cells
(Fig. 3b), which is consistent with the idea that DKK3
overexpression results in the inhibition of canonical Wnt
signaling. In contrast, LKB1 proteins with mutations
aﬀecting either its kinase activity (K78I) or its subcel-
lular localization (SL26) fail to induce b-catenin phos-
phorylation and therefore could potentially activate
canonical Wnt signaling. However, although b-catenin is
phosphorylated in LKB1-expressing cells, it is not de-
graded as expected: amounts of b-catenin in all extracts
are similar.
Regulation of the Wnt/b-catenin pathway is mediated
by the glycogen synthase kinase 3-beta (GSK-3b;
reviewed in Doble and Woodgett 2003)). De-phosphor-
ylation of GSK-3b at residue S9 activates its catalytic
activity, allowing it to phosphorylate its substrate b-
catenin (Harwood 2001). We therefore assayed GSK-3b
activity by Western analysis of protein extracts from
cells transduced with LKB1 WT or mutant LKB1. We
found that GSK-3b is phosphorylated at S9 in unin-
fected HeLa cells, and in cells expressing mutant (K78I
and SL26) but not WT LKB1 proteins (Fig. 3c). These
data demonstrate that LKB1 expression in HeLa cells is
suﬃcient to allow GSK-3b to become active, either by
inhibiting a kinase or activating a phosphatase speciﬁc
for GSK-3b. Furthermore, we show that, in LKB1-WT-
expressing cells, GSK-3b activity correlates with the
presence of phosphorylated b-catenin. These data indi-
cate that LKB1 negatively regulates transcription of
Wnt target genes by inducing-dephosphorylation of
GSK-3b. Therefore, we hypothesize that LKB1 mutants
that are defective in the ability to regulate the phos-
phorylation state of GSK-3b are likely to activate the
canonical Wnt pathway.
Wild-type LKB1 inhibits the canonical Wnt signaling
pathway
Microarray and biochemical data from HeLa cells thus
suggest that LKB1 may inhibit Wnt signaling. There-
fore, loss of functional LKB1 could lead to activation of
the canonical Wnt pathway. We proceeded to test the
hypothesis that LKB1 is a negative regulator of Wnt-
responsive genes and that LKB1 mutants found in PJS
patients are defective for this inhibitory activity on the
Wnt/b-catenin pathway. To explore Wnt signaling,
transcription of a TCF-LEF dependent luciferase
reporter gene was analyzed following co-transfection of
the reporter gene together with expression plasmids for
WT or mutant LKB1. Two reporter genes under the
control of TCF promoters were used to assay the
activity of the canonical Wnt pathway. The TOP-
FLASH plasmid contains multimeric TCF-binding sites
upstream of the luciferase reporter gene, whereas the
FOPFLASH version has mutations in the TCF-binding
sites. Activation of the canonical Wnt pathway is usually
measured by the ratio between the levels of luciferase
activity in cells transfected with the TOPFLASH and
FOPFLASH plasmids. In HeLa cells, this ratio is 1,
indicating that Wnt signaling is not constitutively active.
Therefore in the absence of any positive stimulus we
were unable to draw any conclusions regarding the
inhibitory eﬀect of LKB1 expression on Wnt signaling in
HeLa cells using this reporter system (data not shown).
We then tested the TCF-LEF reporter luciferase in
A549 adenocarcinoma lung epithelial cells which, -like
Hela cells, do not express the endogenous LKB1 gene.
We found weak Wnt signaling in cells that had not been
transfected with any of the LKB1 constructs, since the
TOPFLASH/FOPFLASH ratio was around 2. We
found 30% inhibition of Wnt signaling upon expression
Fig. 4 Wild-type LKB1 inhibits canonical Wnt signaling in A549
lung epithelial cells. a Lysates of parental HeLa cells (-) or cells
tranduced with HA-LKB1-WT, HA-LKB1-K78I or HA-LKB1-
SL26 were prepared 5 days post-infection and fractionated by
SDS-PAGE, and selected endogenous proteins were detected by
immunoblotting with anti-cyclin D1 antibodies. b Constructs
expressing WT or mutant K78I or SL26 LKB1, as well as active
and mutated TCF-LEF luciferase reporter plasmids (TOPFLASH
and FOPFLASH), were transfected into A549 cells. Transcription
of the reporter gene was assayed by measuring luciferase activity
according the manufacturer’s instructions. Values are means
(± SD) of triplicate samples of three independent experiments
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of WT LKB1, whereas the K78I mutant had no eﬀect
and SL26 actually activated signaling by up to 40%
(Fig. 4b). We also found that the level of cyclin D1
protein is higher in cells expressing mutant LKB1 than
in non-transduced HeLa cells, which is consistent with
increased transcription of at least some endogenous Wnt
target genes in LKB1 mutant-expressing cells (Fig. 4a).
This result suggests that LKB1 mutants are indeed able
to activate canonical Wnt signaling on their own, and is
consistent with the presence of less phosphorylated b-
catenin in cells expressing mutant LKB1 than in non-
transduced cells (Fig. 3b). However, in contrast to SL26,
the K78I mutant has no eﬀect on Wnt signal transduc-
tion in A549 cells, suggesting that the ability of LKB1
mutants to activate Wnt signaling could be dependent
on the cell type considered.
Taken together, our data suggest that LKB1 nega-
tively regulates the Wnt/b-catenin pathway and that
activation of this pathway could be a common feature of
PJS mutants. As activation of Wnt signaling has been
implicated in the development of many cancers, includ-
ing colorectal and ovarian cancers (Giles et al. 2003),
this ﬁnding is compatible with the cancer predisposition
of PJS patients.
Other notable transcriptome diﬀerences
Among the other transcriptome diﬀerences listed in
Table 1, several interesting transcripts that appear to be
functionally relevant for the involvement of LKB1 in
tumor suppression, embryogenesis or vasculogenesis
were identiﬁed. One of these encodes transgelin (TAG-
LN alias SM22a), which is a marker for diﬀerentiated
smooth muscle cells and is important in blood vessel
formation (Zhang et al. 2001); its expression is highly
increased in LKB1 expressing cells. Because the P
value for TAGLN was >0.05 in K78I-expressing cells,
TAGLN expression was determined at the mRNA and
protein levels using quantitative qRT-PCR and Western
analysis, respectively. Our data show that TAGLN is
only expressed in LKB1-tranduced cells; the ability to
induce TAGLN expression is abolished by both K78I
and SL26 mutations (Fig. 5a, c).
We also conﬁrmed by qRT-PCR that LKB1 muta-
tions aﬀect the capacity of LKB1 to down-regulate genes
Fig. 5 Expression of exogenous LKB1 in HeLa cells is associated
with mis-regulation of other genes mainly involved in vasculogen-
esis. qRT-PCR was performed on RNA extracts from parental
HeLa cells and from cells expressing WT or mutant (K78I and
SL26) LKB1 proteins. Data are means (± SD) from three
independent experiments analyzed in triplicate. Data are normal-
ized with respect to the housekeeping genes mentioned in Materials
and methods. Data obtained with RNA from HeLa cells served as
reference and the relative changes correspond to the following
ratios: LKB1-WT/HeLa, LKB1-K78I/HeLa, LKB1-SL26/HeLa.
Genes up-regulated by LKB1-WT (such as IGFBP3 and TAGLN)
were tested in a and genes down-regulated by LKB1-WT (such as
FOXF1, BMP6 and RUNX3) were tested in b, c Lysates from
parental HeLa cells (-) or cells tranduced with HA-LKB1-WT, HA-
LKB1-K78I or HA-LKB1-SL26 were prepared 5 days post-
infection and fractionated by SDS-PAGE, and selected endogenous
proteins were detected by immunoblotting with the following
antibodies: anti-ﬁbronectin, anti-IGFBP3, anti-transgelin antibod-
ies. Anti-actin antibodies were used to check that equal amounts of
total protein (50 lg) had been loaded
c
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such FOXF1 (which encodes a transcription factor
important for cell migration; Kalinichenko et al. 2002),
BMP6 (which codes for a signaling molecule important
during development for cell communication; Perr et al.
1999) and RUNX3 (a tumor suppressor gene for gastric
cancer; Li et al. 2002) (Fig. 5b).
We also found that the expression of genes involved
in vasculogenesis, such as LOXL1, PODXL and IG-
FBP3, was similarly aﬀected in cells expressing either
LKB1 mutant. LOXL1 encodes lysyl oxidase-like 1
protein, which catalyzes the oxidative deamination of
lysine residues in elastin. Interestingly, vascular abnor-
malities occur in mice lacking LOXL1 (Liu et al. 2004).
PODXL (Kershaw et al. 1997) and IGFBP3 (Lee et al.
1999) are highly expressed in vascular endothelium cells
and might regulate vascularization. We conﬁrmed by
qRT-PCR and Western analysis that IGFBP3 tran-
scripts are induced upon expression of wild type LKB1
but not mutant proteins (Fig. 5a, c).
The amount of ﬁbronectin in protein extracts from
cells expressing wild type or mutant LKB1 was also
analyzed, since ﬁbronectin levels are reduced in trans-
formed cells (Spicer and Branton 1980). While ﬁbro-
nectin RNA levels are decreased in all transductants
expressing mutant LKB1 (Table 1), the protein level was
found to be reduced only in extracts obtained from
SL26-expressing cells (Fig. 5c). This result supports the
notion that LKB1 mutations have distinct eﬀects and
suggests that the SL26 mutant might be the more potent
promoter of tumorigenesis. Moreover, these data iden-
tify new candidate proteins for involvement in metabolic
pathways regulated by LKB1.
Discussion
This study was designed to investigate the molecular
pathogenesis of PJS by comparing transcription proﬁles
of cells expressing exogenous WT or mutant LKB1. The
use of both K78I and SL26 mutants in our transcrip-
tome analysis makes the present work complementary to
previous array studies performed in lung epithelial A549
(Jimenez et al. 2003) or LKB1 null MEF cells (Bardeesy
et al. 2002). We took advantage of the ability of lentiv-
iral vectors to drive the expression of low levels of LKB1
protein in a homogeneous cell population. In contrast to
previous studies, this allowed us to perform microarray
analysis in growing HeLa cells, simply because LKB1 is
not overexpressed. HeLa cells have been extensively
used to study LKB1 functions because they lack
endogenous LKB1 expression (Smith et al. 2001; Sap-
kota et al. 2002) and therefore are useful for functional
analysis of wild-type or mutant LKB1 proteins. Our
microarray data analysis conﬁrmed the suitability of this
cell line as a model system for the study of LKB1
functions since it is consistent with the activation of
SMAD4/TGF-b signaling upon expression of LKB1,
and with COX2 up-regulation in association with loss of
LKB1 function, two features previously linked to LKB1
function (Smith et al. 2001; Jishage et al. 2002; Rossi
et al. 2002; Wei et al. 2003).
In Lkb1+/ mice, haploinsuﬃciency for LKB1 is
responsible for polyp formation (Jishage et al. 2002). In
humans, despite the fact that loss of heterozygosity
(LOH) aﬀecting the WT allele is found in 70% of tumors
isolated from PJS patients (Hemminki et al. 1997), there
is no evidence that polyposis and cancer predisposition
arise from LOH only. Although further investigations
are necessary to establish that LKB1 mutant alleles are
expressed in PJS patients, comparisons of transcripto-
mes from cells expressing wild-type versus mutant LKB1
proteins highlights signaling pathways that are poten-
tially aﬀected by LKB1 mutations found in PJS patients.
Transcriptome comparisons of cells expressing mu-
tant versus wild type LKB1 show that: (1) the LKB1-
dependent transcription of some genes is aﬀected by
both K78I and SL26 mutations, and (2) these LKB1
mutations also have diﬀerent eﬀects on overall gene
expression. We determined that almost all genes aﬀected
by the LKB1-K78I mutant (which lacks kinase activity)
are also misregulated in cells that express the SL26
mutant (which accumulates in the nucleus). This result is
surprising, because SL26 retains its kinase activity, as
indicated by in vitro tests (data not shown), but conﬁrms
previous evidence that both the kinase activity and the
cytoplasmic localization of LKB1 are necessary for this
protein to perform its normal cellular function (Nezu
et al. 1999). This implies that at least some of the targets
of LKB1 are likely to be cytoplasmic.
In addition, de novo expression of YFP-LKB-SL26
aﬀects speciﬁc genes, whose expression is not modiﬁed
by either YFP-LKB-WT or YFP-LKB-K78I. This sug-
gests that nuclear accumulation of SL26 induces a spe-
ciﬁc cellular response and that this particular mutant
might have acquired new functions, probably phos-
phorylating novel nuclear substrates.
Many amino acid substitutions found in PJS patients
result in loss of kinase activity. How the SL26 mutation
leads to the PJS phenotype has remained an open
question. Our microarray experiment partially answers
this question by pinpointing several genes that are
commonly aﬀected in both K78I- and SL26-expressing
cells. In agreement with the proposed function of LKB1,
genes identiﬁed by our microarray data as being diﬀer-
ently regulated between cells expressing WT or mutant
LKB1 proteins are mostly involved in cellular diﬀeren-
tiation, and in cell adhesion and migration. Several of
these genes play a role in vasculogenesis (LOX, IGFBP3,
TAGLN, and PODXL). This ﬁnding is of interest, since
Lkb1/ mice exhibit vascular abnormalities, and show
a complete absence of vascular smooth muscle cells in
the dorsal aorta and somites (Ylikorkala et al. 2001).
Interestingly, we found several of the genes that are
misregulated in mutant-expressing cells are involved in
Wnt signaling, supporting recent observations that
LKB1 regulates developmental processes through this
pathway (Ossipova et al. 2003; Spicer et al. 2003). We
identiﬁed DKK3, WNT5B and FZD2 as potential
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candidates for this regulation. Several studies provide
evidence that WNT5A (a close homolog of WNT5B) is
able to antagonize the Wnt/b-catenin pathway (Miller
et al. 1999). WNT5A may act as a tumor suppressor
since it is able to suppress transformation by WNT1.
Furthermore, expression of Xenopus Wnt5A leads to an
increase in Ca2+ ﬂuxes and to activation of protein ki-
nase C (Miller et al. 1999). In contrast, very little is
known about functions of WNT5B, and further inves-
tigations are necessary to establish whether its functions
are similar to those of WNT5A. FZD2, WNT5A and
PLC activate the Wnt/Ca2+ pathway, while proteins
belonging to the Dickkopf family inhibit the Wnt/b-
catenin pathway (Miller 2002). Based on the sequence
homologies between WNT5A and WNT5B, as well as
those between DKK1 and DKK3, our microarray data
suggest that LKB1 could be a molecular switch for Wnt
signaling, activating the Wnt/Ca2+ pathway and inhib-
iting Wnt/b-catenin signaling. In contrast, LKB1 mu-
tants might be impaired in this switch regulation. As the
canonical Wnt pathway is essential for the integrity of
intestinal crypt cells and for epithelium homeostasis
(Pinto et al. 2003), failure to properly regulate this
pathway could explain the propensity of PJS patients to
develop polyposis.
LKB1 has recently been reported to be a regulator
of GSK-3b activity (Ossipova et al. 2003). Experi-
mental data presented in that report suggested that
GSK-3b might be a substrate for LKB1, since reduc-
tion of LKB1 expression resulted in diminished phos-
phorylation of GSK-3b at residue S9. In contrast, we
found that de novo LKB1 expression results in
dephosphorylation of GSK-3b at the same S9 residue.
Hence, our data support the idea that GSK-3b is not a
direct substrate for LKB1. Furthermore, our data are
consistent with the failure of immunoprecipitated
Xenopus LKB1 (XEEK1) to directly phosphorylate the
GSK-3b protein (Ossipova et al. 2003). Our ﬁnding
that LKB1 protein activates GSK-3b is particularly
instructive since both proteins have previously been
implicated in regulating cell polarity (Watts et al. 2000;
Etienne-Manneville and Hall 2003; Martin and St
Johnston 2003; Baas et al. 2004a). The inability of
mutant forms of LKB1 to activate GSK-3b might
therefore be responsible for the lethality of mutations
in LKB1 orthologs in C. elegans and D. melanogaster,
as well as in Lkb1/ knockout mice.
Finally, we show that expression of LKB1 inhibits
Wnt signaling in A549 cells, another cell line that lacks
endogenous LKB1 (Carretero et al. 2004). However, in
transduced HeLa cells, LKB1-mediated phosphoryla-
tion of b-catenin did not seem to lead to degradation of
the latter by the proteosome. In order to explain this
apparently conﬂicting result, b-catenin localization was
investigated by performing immunostaining for total
and phosphorylated b-catenin in HeLa cells expressing
WT or mutant LKB1 proteins. Upon expression of
mutant LKB1, the number of cells with nuclear b-cate-
nin staining is increased, whereas b-catenin localizes
preferentially at membranes in non-transduced cells and
in the cytoplasm in cells expressing WT LKB1 (data not
shown). One possible explanation for the accumulation
of b-catenin in WT LKB1 expressing cells is that, upon
LKB1 expression, phosphorylated b-catenin is not
ubiquitinated and therefore not targeted for degrada-
tion. Although we cannot explain how LKB1 blocks
Wnt signal without promoting b-catenin proteolysis, this
result is consistent with the eﬀect of LKB1 expression in
HCT116 cells (in which one b-catenin allele is mutated at
Ser45 and cannot be targeted for degradation to the
proteosome). Although TCF/b-catenin dependent tran-
scription is constitutively activated in this particular
HCT116 cell line, exogenous expression of LKB1
decreases Wnt signaling by 50% (data not shown). This
observation supports the notion that degradation of
b-catenin might be unrelated to the ability of LKB1 to
inhibit Wnt signaling.
In A549 cells, the LKB1 kinase activity is necessary
for this inhibition. In contrast, SL26 stimulates tran-
scription of Wnt target genes, as revealed using a re-
porter gene and by the response of the endogenous
target gene encoding cyclin D1. This probably occurs
because SL26 is impaired in its ability to regulate
GSK-3b activity, resulting in the presence of unphos-
phorylated b-catenin in SL26-expressing cells. This
ﬁnding is of interest, as somatic mutations at codons
41 and 37 in the b-catenin gene (Miyaki et al. 2000),
as well as nuclear accumulation of b-catenin (Back
et al. 1999), have been reported in gastrointestinal
polyps from PJS patients. Notably, mutations in the
APC gene that are associated with familial adenoma-
tous polyposis (FAP) result in the development of
polyposis and colon carcinomas through activation of
the Wnt/b-catenin pathway (Giles et al. 2003). This
suggests that mutations in genes that regulate b-cate-
nin phosphorylation are generally involved in the
development of polyposis and cancer predisposition.
The ability of the SL26 mutant to activate the Wnt/b-
catenin pathway is consistent with this hypothesis. The
question whether activation of this pathway, either by
the positive eﬀect of a gain-of-function LKB1 mutant
(such as SL26) or by loss of the inhibitory LKB1
function, is a common feature of PJS mutants must
remain open. As activation of the Wnt pathway has
been implicated in the development of many cancers,
including colorectal and ovarian cancers (Giles et al.
2003), this ﬁnding is compatible with the cancer pre-
disposition of PJS patients. Moreover, our study has
identiﬁed novel candidates for a second potential PJS
locus.
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